NCT06762470View on ClinicalTrials.gov

Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma

Active, not recruitingOBSERVATIONAL
Enrollment

325

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Histopathological Diagnosis of Nasopharyngeal CarcinomaPatients with Nasopharyngeal Carcinoma Without Distant Metastases After AJCC/UACC 8th Edition
Trial Locations (1)

330029

Jiangxi Cancer Hospital, Nanchang

All Listed Sponsors
lead

Jiangxi Provincial Cancer Hospital

OTHER

NCT06762470 - Prognostic Value of CD4/CD8 Ratio in Patients with Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter